title: [Use of naftidrofuryl in angiology].
abstract: The review analyses the role of serotonin in the development of pathological processes in angiological patients, showing its negative role in aggravating chronic and acute ischaemia of various organs (brain, myocardium, extremities) both at the expense of vasoconstriction and due to an increase in blood platelet aggregation of blood platelets and erythrocytes, followed by analysis of clinical efficacy of naftidrofuryl) - serotonin 5-HT2 receptor antagonist. Results of numerous randomized trials confirmed its efficacy and safety in treatment of angiological patients, being superior to other vasotropic drugs (cilostazol, pentoxyphyllin, nicotinic acid).
authors.forename: M R
authors.initials: MR
authors.lastname: Kuznetsov
authors.forename: I V
authors.initials: IV
authors.lastname: Kosykh
authors.forename: S M
authors.initials: SM
authors.lastname: Iumin
authors.forename: N V
authors.initials: NV
authors.lastname: Kunitsyn
authors.forename: V F
authors.initials: VF
authors.lastname: Kuznetsova
authors.forename: V Iu
authors.initials: VIu
authors.lastname: Tolstikhin
authors.forename: L A
authors.initials: LA
authors.lastname: Magnitskiĭ
mesh_terms: D006801:Humans; D007511:Ischemia / Q000145:classification / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D009257:Nafronyl / Q000494:pharmacology*; D016032:Randomized Controlled Trials as Topic; D044348:Receptors, Serotonin, 5-HT2 / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism*; D016896:Treatment Outcome; D014661:Vasoconstriction / Q000187:drug effects / Q000502:physiology; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D044348:Receptors, Serotonin, 5-HT2; D014665:Vasodilator Agents; D012701:Serotonin; D009257:Nafronyl